US stocks were mixed Thursday as President Trump's sweeping tariffs hit dozens of US trade partners after his self-imposed ...

Mounjaro manufacturer Eli Lilly has unveiled the test results of its new oral GLP-1 medication, orforglipron. The obesity pill, which is designed to be taken daily by patients who are severely ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, Eli Lilly announced the topline results from its SURPASS-CVOT ...

Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The ...

U.S. equities were mixed at midday in response to more corporate earnings reports and the start of new U.S. tariffs.

Eli Lilly reports strong Q2 2025 growth, driven by Mounjaro & Zepbound. Highlights include increased guidance, pipeline updates, and key clinical milestones.

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...